Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dolutegravir Sodium,Lamivudine,Tenofovir Disproxil Fumurate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : USFDA approved a combination drug Dolutegravir, Lamivudine and Tenofovir Disproxil Fumurate a complete regimen for treatment of HIV‐1 infection in adults and pediatric patients weighing at least 35kgs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2023
Lead Product(s) : Dolutegravir Sodium,Lamivudine,Tenofovir Disproxil Fumurate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Strides Receives Tentative USFDA Approval for Dolutegravir Tablets
Details : USFDA approved a generic verion of Dolutegravir for the treatment of HIV‐1 infection in adults and pediatric patients weighing at least 35kgs. It inhibits HIV-integrase which is necessary for viral cell replication.
Brand Name : Tivicay-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2023
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ViiV Healthcare Announces FDA Approval Of Dovato for Adolescents with HIV
Details : Dovato (dolutegravir and lamivudine) is the first oral two-drug single-tablet regimen for people aged 12 and older living with HIV.
Brand Name : Dovato
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2024
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Brand Name : Tivicay
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2024
Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : AIDS Healthcare Foundation
Deal Size : Not Applicable
Deal Type : Not Applicable
AHF Praises Colombia's Stand for Accessible HIV Treatment
Details : Dolutegravir tablets is a HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Brand Name : Tivicay-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2023
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : AIDS Healthcare Foundation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Abacavir,Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension is indicated for the treatment of HIV-1 infection in paediatric patients weighing at least 6 kg.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2023
Lead Product(s) : Abacavir,Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Gets US FDA Tentative Approval for Dolutegravir Tablets for Oral Suspension
Details : Dolutegravir tablets is a HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Brand Name : Tivicay-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 04, 2023
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The combination inhibits HIV-1 replication, in which dolutegravir inhibits HIV integrase and blocks the strand transfer step of retroviral DNA integration where emtricitabine and tenofovir alafenamide inhibits the activity of the HIV-1 reverse transcript...
Brand Name : Dolutegravir/Emtricitabine/Tenofovir Alafenamide-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2023
Lead Product(s) : Dolutegravir Sodium,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets
Details : Dolutegravir Sodium, where dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used as an oral combination for the treatment of HIV-1 infections in treatment-naive patients.
Brand Name : Dolutegravir/Rilpivirine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Dovato (dolutegravir sodium), is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) o...
Brand Name : Dovato
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2022
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?